Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient

Actas Dermosifiliogr (Engl Ed). 2018 Sep;109(7):584-601. doi: 10.1016/j.ad.2018.03.013. Epub 2018 Jun 2.
[Article in English, Spanish]

Abstract

Patients with chronic inflammatory diseases being treated with immunosuppressive drugs, and with tumor necrosis factor inhibitors in particular, have an increased risk of infection by Mycobacterium tuberculosis. Screening for latent tuberculosis infection and preventive therapy to reduce the risk of progression to active tuberculosis are mandatory in this group of patients. This updated multidisciplinary consensus document presents the latest expert opinions on the treatment and prevention of tuberculosis in candidates for biologic therapy and establishes recommendations based on current knowledge relating to the use of biologic agents.

Keywords: Biologic therapy; Consenso; Consensus; Hidradenitis suppurativa; Hidrosadenitis supurativa; Psoriasis; Terapias biológicas; Tuberculosis.

Publication types

  • Consensus Development Conference
  • Practice Guideline

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / therapeutic use*
  • Biological Therapy / adverse effects*
  • Drug Monitoring
  • Hidradenitis Suppurativa / drug therapy
  • Humans
  • Immunity, Cellular
  • Latent Tuberculosis / diagnosis
  • Latent Tuberculosis / drug therapy*
  • Patient Selection
  • Psoriasis / drug therapy
  • Risk
  • T-Lymphocyte Subsets / immunology
  • Tuberculosis / drug therapy
  • Tuberculosis / prevention & control*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antitubercular Agents
  • Tumor Necrosis Factor-alpha